

October 21, 2026

News Release

Company: Olympus Corporation

Bob White, Director, Representative Executive Officer, President and CEO

(Code: 7733, Prime, Tokyo Stock Exchange)

Contact: Takaaki Sakurai, Vice President, Investor Relations

TEL: +81-42-642-2111

Notice Regarding Issuance of Import Alerts by FDA

Olympus Corporation ("Olympus" or the "Company") hereby announces that on October 19, 2026 (U.S. time), the United States Food and Drug Administration ("FDA") published import alerts (the "Import Alerts") for certain products manufactured at certain Olympus facilities, namely Olympus Medical Systems Corporation (Hinode, Japan), Shirakawa Olympus Co., Ltd. (Japan) and Aomori Olympus Co., Ltd. (Japan). This action prevents the import of the specified products into the U.S. until further notice.

The Company has reviewed the action and does not expect the Import Alerts to have an incremental impact on its consolidated financial results for the fiscal year ending March 31, 2027. The Company's previously disclosed guidance for the same period remains unchanged.

The Company does not expect any material impact on customers. Affected products already in customers' possession remain safe and effective when used according to their Instructions for Use. At this time, the Import Alerts do not affect the import of these products into any other countries globally.

With patient safety as its top priority, Olympus is committed to ensuring that its products meet the highest quality standards and supporting the customers and healthcare professionals who depend on them. The Company also remains committed to working transparently and constructively with the FDA to address the agency's outstanding concerns.